title: Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor-positive canine mammary carcinomas.
abstract: Neoadjuvant treatment of canine mammary carcinomas with the progesterone receptor (PR) antagonist aglepristone has a PR expression-related inhibiting effect on proliferation index (PI). The aim of this study was to evaluate the effect of the treatment in the disease-free period (DFP) and overall survival (OS) of canine mammary carcinomas. Fifty female dogs with mammary carcinomas were treated with aglepristone (n = 34) or oil vehicle (n = 16) before surgery (day 15). PR expression and PI were analysed by immunohistochemistry in samples taken at days 1 and 15. Epidemiological and clinicopathological data were assessed. DFP and OS data were retrieved every 4-6 months for at least 24 months after surgery. Aglepristone treatment increased DFP of animals bearing PR+ tumours with size smaller than 3 cm, complex and mixed tumours, with histologic grades I and II, and with PI ≤ 10%. Although further studies are necessary, current evidence points to treatment with aglepristone as useful for the management of canine mammary tumours.
authors.affiliation: Department of Comparative Pathology, Veterinary Medicine Faculty, University of Córdoba, Córdoba, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Guil-Luna
authors.affiliation: Department of Comparative Pathology, Veterinary Medicine Faculty, University of Córdoba, Córdoba, Spain.
authors.forename: Y
authors.initials: Y
authors.lastname: Millán
authors.affiliation: Small Animal Clinic Thor, Córdoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: De Andres
authors.affiliation: Small Animal Clinic Canymar, Cádiz, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Rollón
authors.affiliation: Small Animal Clinic Recuerda, Granada, Spain.
authors.forename: V
authors.initials: V
authors.lastname: Domingo
authors.affiliation: Department of Comparative Pathology, Veterinary Medicine Faculty, University of Córdoba, Córdoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: García-Macías
authors.affiliation: Department of Comparative Pathology, Veterinary Medicine Faculty, University of Córdoba, Córdoba, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Sánchez-Céspedes
authors.affiliation: Department of Comparative Pathology, Veterinary Medicine Faculty, University of Córdoba, Córdoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Martín de Las Mulas
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D004285:Dogs; D004963:Estrenes / Q000627:therapeutic use*; D005260:Female; D015674:Mammary Neoplasms, Animal / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D020360:Neoadjuvant Therapy; D011379:Prognosis; D011980:Receptors, Progesterone / Q000378:metabolism*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004963:Estrenes; D011980:Receptors, Progesterone; C419063:aglepristone
keywords: comparative oncology; oncology; pathology; small animal; tumour biology